Let's Talk HIV

Impuls – The ViiV Healthcare Podcast

Dovato (DTG+3TC) and adherence

What do we know about Dovato and adherence? Annelies van der Leeden and Marcel Out, both working at ViiV Healthcare, discuss this topic on the basis of a publication on adherence in the GEMINI study (Dutch spoken)

- -
  1. Ait-Khaled M et al. HIV Res Clin Pract 2021 Dec 16;1-6 DOI 10.1080/25787489.2021.2016303
  2. Cahn P et al. Lancet. 2019;393(10167):143-155
  3. Cahn P et al. AIDS. 2022;36(1):39-48.
  4. van Wyk J et al. Clin Infect Dis. 2020;ciz1243:1-10
  5. Patel et al. Infect Dis Ther. 2021;10(4):2051-2070.
  6. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Version: Jan 2022. Assessed March 2022.
  7. DOVATO Summary of Product characteristics, March 2022

DOVATO is indicated for the treatment of HIV-1 in adults and adolescents above 12 years weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.7

Impulse, the ViiV Healthcare podcast, all about ViiV

Feedback or Suggestion?

Do you have any feedback or would like to suggest a topic for a podcast or a read?

Contact us

PM-NL-HVX-WCNT-220003, March 2022